Fujifilm to invest $1.2 bln in North Carolina plant in biopharma expansion (updated)

WuXi Biologics (Cayman)

11/04/2024 19:07

(Adds Nikkei report on overall biopharma investment plan,
paragraphs 3-4)
       TOKYO, April 12 (Reuters) - Japan's Fujifilm  4901.T 
will invest $1.2 billion to expand its North Carolina plant as
part of its plans to expand biopharmaceutical contract
manufacturing businesses in the United States and Europe, the
company said on Thursday.
    The investment will generate an additional 680 jobs at the
unit Fujifilm Diosynth Biotechnologies' facility in Holly
Springs, North Carolina by 2031, the company said in a
statement.
    The Nikkei business daily reported on Friday that Fujifilm
was planning a total $4.5 billion investment by 2028 in its
global biopharmaceutical manufacturing sites, including in Japan
and Europe.
        Fujifilm is mulling over the expansion to quintuple its
cell culture production capacity to about 750,000 litres and
better compete against rivals including Switzerland's Lonza
 LONN.S , China's Wuxi Biologics  2269.HK  and South Korea's
Samsung Biologics  207940.KS , Nikkei said.
  

 (Reporting by Kantaro Komiya; Editing by Chris Reese and Chizu
Nomiyama)
 ((Kantaro.Komiya@thomsonreuters.com; Twitter: @kantarokomiya;))